Background: To date, most work delineating the usefulness of neuron-specific enolase (NSE) as a marker for acute ischemic stroke has been inconclusive. This study had the following objectives: (1) to determine whether serum concentrations of NSE correlate with time of onset of stroke symptoms, volume of infarcted tissue, stroke severity, functional outcome, or length of hospital stay; (2) to determine whether serial measurements of NSE levels are useful markers for ongoing brain ischemia, and (3) to determine whether NSE levels at various time intervals are significantly higher in patients with stroke than in controls. Methods: All abstracts and published full reports identified as potentially relevant by the literature search were independently assessed for inclusion in the review by each reviewer. Twelve studies (including 597 patients) satisfied the entry criteria for this qualitative analysis. Results: In 4 studies, time of onset of stroke symptoms was compared with time of first detectable NSE levels, which ranged from 4 to 8 h after stroke onset. In 7 studies, NSE levels increased with increased size of stroke, but in 2 studies there was no correlation. In the 2 studies that compared stroke severity with NSE levels, high NSE levels generally indicated worse outcome, but at low NSE levels the results were equivocal. In 7 studies, functional outcome at hospital dismissal and follow-up was compared with NSE levels; in 4, there was no correlation. Conclusions: The serum level of NSE does seem to be higher in stroke patients than in controls, and it does appear to correlate with volume of infarcted tissue. However, it does not appear to correlate with functional outcome, and its relationship to stroke severity is unclear. This may be explained at least in part by the disparity in sampling times because the NSE level has been shown to peak after 24 h in most studies. Hence, the more delayed the sampling, the greater the correlation with stroke severity.

Keywords:
Neuron-specific enolase, Serum marker, Stroke
1.
Jauch EC: Diagnosis of stroke: the use of serum markers. Adv Emerg Card Neurovasc Care 2002;39–45.
2.
Hatfield RH, McKernan RM: CSF neuron-specific enolase as a quantitative marker of neuronal damage in a rat stroke model. Brain Res 1992;577:249–252.
3.
Barone FC, Clark RK, Price WJ, White RF, Feuerstein GZ, Storer BL, et al: Neuron-specific enolase increases in cerebral and systemic circulation following focal ischemia. Brain Res 1993;623:77–82.
4.
Butterworth RJ, Wassif WS, Sherwood RA, Gerges A, Poyser KH, Garthwaite J, et al: Serum neuron-specific enolase, carnosinase, and their ratio in acute stroke: an enzymatic test for predicting outcome? Stroke 1996;27:2064–2068.
5.
Cunningham RT, Watt M, Winder J, McKinstry S, Lawson JT, Johnston CF, et al: Serum neurone-specific enolase as an indicator of stroke volume. Eur J Clin Invest 1996;26:298–303.
6.
Cunningham RT, Young IS, Winder J, O’Kane MJ, McKinstry S, Johnston CF, et al: Serum neurone specific enolase (NSE) levels as an indicator of neuronal damage in patients with cerebral infarction. Eur J Clin Invest 1991;21:497–500.
7.
Fassbender K, Schmidt R, Schreiner A, Fatar M, Muhlhauser F, Daffertshofer M, et al: Leakage of brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic stroke. J Neurol Sci 1997;148:101–105.
8.
Gruener N, Gross B, Gozlan O, Barak M: Increase in superoxide dismutase after cerebrovascular accident. Life Sci 1994;54:711–713.
9.
Hill MD, Jackowski G, Bayer N, Lawrence M, Jaeschke R: Biochemical markers in acute ischemic stroke. CMAJ 2000;162:1139–1140.
10.
Missler U, Wiesmann M, Friedrich C, Kaps M: S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 1997;28:1956–1960.
11.
Oh SH, Lee JG, Na SJ, Park JH, Choi YC, Kim WJ: Prediction of early clinical severity and extent of neuronal damage in anterior-circulation infarction using the initial serum neuron-specific enolase level. Arch Neurol 2003;60:37–41.
12.
Schaarschmidt H, Prange HW, Reiber H: Neuron-specific enolase concentrations in blood as a prognostic parameter in cerebrovascular diseases. Stroke 1994;25:558–565.
13.
Stevens H, Jakobs C, de Jager AE, Cunningham RT, Korf J: Neurone-specific enolase and N-acetyl-aspartate as potential peripheral markers of ischaemic stroke. Eur J Clin Invest 1999;29:6–11.
14.
Sulter G, Elting JW, De Keyser J: Increased serum neuron specific enolase concentrations in patients with hyperglycemic cortical ischemic stroke. Neurosci Lett 1998;253:71–73.
15.
Wunderlich MT, Ebert AD, Kratz T, Goertler M, Jost S, Herrmann M: Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke 1999;30:1190–1195.
16.
Karkela J, Bock E, Kaukinen S: CSF and serum brain-specific creatine kinase isoenzyme (CK-BB), neuron-specific enolase (NSE) and neural cell adhesion molecule (NCAM) as prognostic markers for hypoxic brain injury after cardiac arrest in man. J Neurol Sci 1993;116:100–109.
17.
Martens P, Raabe A, Johnsson P: Serum S-100 and neuron-specific enolase for prediction of regaining consciousness after global cerebral ischemia. Stroke 1998;29:2363–2366.
18.
Niebroj-Dobosz I, Rafalowska J, Lukasiuk M, Pfeffer A, Mossakowski MJ: Immunochemical analysis of some proteins in cerebrospinal fluid and serum of patients with ischemic strokes. Folia Neuropathol 1994;32:129–137.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.